title: [Vidarabine-interferon combination in patients with chronic viral hepatitis B of mutant form. Efficiency and tolerability during a pilot study].
authors.forename: M
authors.initials: M
authors.lastname: Durand
authors.forename: F
authors.initials: F
authors.lastname: Bost
authors.forename: M
authors.initials: M
authors.lastname: Maynard
authors.forename: M
authors.initials: M
authors.lastname: Baud
authors.forename: M
authors.initials: M
authors.lastname: Cohard
authors.forename: J P
authors.initials: JP
authors.lastname: Zarski
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy* / Q000821:virology; D006521:Hepatitis, Chronic / Q000188:drug therapy / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011994:Recombinant Proteins; D014740:Vidarabine / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014740:Vidarabine
vernacular_title: Association vidarabine-interféron chez les patients atteints d'hépatite virale chronique B à forme mutante. Efficacité et tolérance au cours d'une étude pilote.